T cell receptors targeting pik3ca mutations and uses thereof
AssigneeMemorial Sloan Kettering Cancer Center
InventorsChristopher Klebanoff, Smita S. Chandran
Life of this patent
Estimating the term…
Abstract
The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., breast cancer). It relates to mutant PIK3CA-targeted TCRs that specifically target a mutant PIK3CA peptide (e.g., a human mutant PIK3CA peptide), and immunoresponsive cells comprising such TCRs. The presently disclosed mutant PIK3CA peptide-specific TCRs have enhanced immune-activating properties, including anti-tumor activity.
Claims30
AT cell receptor (TCR) comprising an extracellular domain, a transmembrane domain, and an intracellular domain, wherein the extracellular domain specifically targets a PIK3CA polypeptide comprising a mutation, and comprises:
- a) an α chain variable region that comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 41, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 42, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 43;
- and
- b) a β chain variable region that comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 44, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 45, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 46 and a β chain variable region.
Dependencies are inferred from the claim text.